**Specifications table**TableSubject areaBiologyMore specific subject areaGenomics, tigecycline-resistant *Enterobacter cloacae*Type of dataFigure, tableHow data was acquiredThe data was acquired on HiSeq^TM^ 4000 (Illumina) sequencing platformData formatAnalysedExperimental factorsGenomic DNA from pure cultureExperimental featuresIsolation of bacteria, genome sequencing, draft genome assembly and annotationData source locationHangzhou, ChinaData accessibilityData is with this article, also this Whole Genome Shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession number PJZE00000000.(<http://www.ncbi.nlm.nih.gov/nuccore/PJZE00000000>)

**Value of the data**•This data may help us to understand the genomic feature and molecular characteristic of this bacterial pathogen.•This data may help us to understand the resistance gene diversity of this bacterial pathogen.•The genome sequence of *Enterobacter cloacae* TREC1 can be used as a reference sequence for comparative analysis of tigecycline-resistant *E. cloacae* aimed to reveal the mechanism of tigecycline-resistance in CRE.

1. Data {#s0005}
=======

The draft genome sequence of *Enterobacter cloacae* TREC1 consisted of 74 contigs that comprised 5,322,835 bp, and the overall GC content of this strain amounted to 54.63%. In total, 57 tRNA genes, 5 rRNA operons and 5108 protein-coding sequences were identified by the RAST server, respectively. According to the MLST scheme of *E. cloacae*, TREC1 belongs to sequence type ST93. The genome also contains one intact and one incomplete prophage sequences, three CRISPR sequences and several IS elements: the majority belonging to the IS*3* and IS*5* families. The resistance genes present in the genome of the isolate are presented in [Table 1](#t0005){ref-type="table"}. We identified the aminoglycoside resistance genes *armA*, *aadA5*, *strA* and *aph(6)-Id*; the beta-lactam resistance genes *bla*~CTX-M-14~, *bla*~ACT-7~, *bla*~KPC-2~, and *bla*~CTX-M-3~; the fluoroquinolone resistance genes *qnrS1* and *qnrA1*; the fosfomycin resistance gene *fosA*; the macrolide, Lincosamide and Streptogramin B resistance genes *msr(E)* and *mph(E)*; the phenicol resistance gene *catA2*; the sulphonamide resistance genes *sul1* and *sul2*; the trimethoprim resistance genes *dfrA1* and *dfrA14*; and the tetracycline resistance gene *tetA*. Ceftazidime, cefepime, imipenem, meropenem, piperacillin/tazobactam, cefoperazone/sulbactam, fosfomycin, amikacin, ciprofloxacin, trimethoprim/sulfamethoxazole, minocycline, tigecycline and colistin were used in the susceptibility testing. The isolate was resistant to all antimicrobials above except colistin. The MIC values are presented in [Table 2](#t0010){ref-type="table"}. Isolate *E. cloacae* TREC1 not only produce KPC-2 carbapenemase, but are also resistant to tigecycline bringing a great challenge to clinical treatment. The relative expression level of efflux pump genes (*acrA*, *acrB*, *oqxA* and *oqxB*) in the tigecycline-resistant isolate TREC1 were examined by qRT-PCR. Relative expression of each target gene was calibrated against the corresponding expression of a tigecycline-susceptible isolate *E. cloacae* TSEC (expression = 1), which was served as the control. According to the results ([Table 3](#t0015){ref-type="table"}), the expression level of efflux pump AcrAB was increased 2--3 fold relative to the susceptible isolate. The expression level of efflux pump OqxAB between TREC1 and TSEC was not significant. Tetracycline resistant gene *tetA* was found in TREC1, but no mutation was detected.Table 1Antimicrobial resistance genes in isolate *E. cloacae* TREC1.Table 1**Resistance gene%identityHSP length/queryContigPosition in contigPredicted phenotypeAccession number**Aminoglycoside*armA*99.87774/774contig_571189.1962Aminoglycoside resistance[AY220558](ncbi-n:AY220558){#ir0005}*aadA5*100789/789contig_58150.938Aminoglycoside resistance[AF137361](ncbi-n:AF137361){#ir0010}*strA*100804/804contig_595401.6204Aminoglycoside resistance[M96392](ncbi-n:M96392){#ir0015}*aph(6)-Id*100837/837contig_596204.7040Aminoglycoside resistance[M28829](ncbi-n:M28829){#ir0020}  Beta-lactam*bla*~CTX-M-14~100876/876contig_851618.2493Beta-lactam resistance[AF252622](ncbi-n:AF252622){#ir0025}*bla*~ACT-7~99.561146/1146contig_819,282.20427Beta-lactam resistance[FJ237368](ncbi-n:FJ237368){#ir0030}*bla*~KPC-2~100882/882contig_543990.4871Beta-lactam resistance[AY034847](ncbi-n:AY034847){#ir0035}*bla*~CTX-M-3~100876/876contig_73413.1288Beta-lactam resistance[EF437434](ncbi-n:EF437434){#ir0040}  Fluoroquinolone*qnrS1*100657/657contig_723,019.23675Quinolone resistance[AB187515](ncbi-n:AB187515){#ir0045}*qnrA1*99.85657/657contig_7054.710Quinolone resistance[AY070235](ncbi-n:AY070235){#ir0050}  Fosfomycin*fosA*98.12426/426contig_27322,842.323267Fosfomycin resistance[AEXB01000013](ncbi-wgs:AEXB01000013){#ir0055}  MLS - Macrolide, Lincosamide and Streptogramin B*msr(E)*1001476/1476contig_574261.5735Macrolide, Lincosamide and Streptogramin B resistance[EU294228](ncbi-n:EU294228){#ir0060}*mph(E)*100885/885contig_575792.6676Macrolide resistance[EU294228](ncbi-n:EU294228){#ir0065}  Phenicol*catA2*96.11642/642contig_97749.1390Phenicol resistance[X53796](ncbi-n:X53796){#ir0070}  Sulphonamide*sul1*100840/840contig_712179.3018Sulphonamide resistance[AY224185](ncbi-n:AY224185){#ir0075}*sul2*100816/816contig_363828.4643Sulphonamide resistance[GQ421466](ncbi-n:GQ421466){#ir0080}  Tetracycline*tetA*1001200/1200contig_831471.2670Tetracycline resistance[AJ517790](ncbi-n:AJ517790){#ir0085}  Trimethoprim*dfrA1*100474/474contig_581455.1928Trimethoprim resistance[JQ690541](ncbi-n:JQ690541){#ir0090}*dfrA14*99.59483/483contig_730.512Trimethoprim resistance[DQ388123](ncbi-n:DQ388123){#ir0095}Table 2MICs of the antibiotics tested in *E. cloacae* TREC1.Table 2**AntibioticsMIC(mg/L)**ceftazidime[a](#tbl2fna){ref-type="table-fn"}256cefepime[a](#tbl2fna){ref-type="table-fn"}\>256imipenem[a](#tbl2fna){ref-type="table-fn"}256meropenem[a](#tbl2fna){ref-type="table-fn"}128piperacillin/tazobactam[a](#tbl2fna){ref-type="table-fn"}\>256cefoperazone/sulbactam[a](#tbl2fna){ref-type="table-fn"}\>256fosfomycin[a](#tbl2fna){ref-type="table-fn"}\>256amikacin[a](#tbl2fna){ref-type="table-fn"}\>256ciprofloxacin[b](#tbl2fnb){ref-type="table-fn"}\>32trimethoprim/sulfamethoxazole[b](#tbl2fnb){ref-type="table-fn"}\>32minocycline[b](#tbl2fnb){ref-type="table-fn"}16tigecycline[c](#tbl2fnc){ref-type="table-fn"}8colistin[c](#tbl2fnc){ref-type="table-fn"}0.25[^2][^3][^4]Table 3Expression level of *acrA*, *acrB*, *oqxA* and *oqxB* in TREC1 compare with a tigecycline-susceptible isolate *E. cloacae* TSEC.Table 3IsolateRelative expression[a](#tbl3fna){ref-type="table-fn"}MIC (mg/L)[b](#tbl3fnb){ref-type="table-fn"}*acrAacrBoqxAoqxB*TSEC11110.25TREC12.86 ± 0.253.07 ± 0.291.24 ± 0.181.06 ± 0.218[^5][^6]

2. Experimental design, materials and methods {#s0010}
=============================================

Isolate *E. cloacae* TREC1 was recovered from a blood sample of a male hospitalised patient in Hangzhou, Zhejiang province, China, in 2017. The isolate was preliminarily identified using the VITEK 2 system (bioMérieux, France) and was further confirmed by 16S rRNA gene sequencing. Antimicrobial susceptibility testing was performed according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). The MICs of tigecycline and colistin were determined using standard broth microdilution tests with fresh (\<12 h) Mueller-Hinton broth (Cation-adjusted, Oxoid LTD, Basingstoke, Hampshire, England). The MICs of other antimicrobial agents were determined using the agar dilution method and Etest method. Whole genome sequencing has increasingly being applied to clinical practice server [@bib1]. The genome of *E. cloacae* TREC1 was sequenced using the Illumina HiSeq^TM^ 4000 platform (Illumina Inc., San Diego, CA, USA) following the paired-end 2 × 150 bp protocol. The whole genome sequence was assembled using CLC Genomics Workbench 10.0 software (Qiagen, Valencia, CA) and annotated by the Rapid Annotation System Technology (RAST) server [@bib2]. The pie chart demonstrated the counts for each subsystem feature and the subsystem coverage ([Fig. 1](#f0005){ref-type="fig"}). *In silico* Multilocus sequence typing (MLST) analysis was performed using the PubMLST database. Resistance-related genes were analysed using ResFinder 3.0 [@bib3]. Further bioinformatics analysis, such as identification of insertion elements (IS), prophage sequences and clustered regularly interspaced short palindromic repeat (CRISPR) sequences were predicted by application of ISfinder, PHASTER and CRISPRFinder, respectively [@bib4], [@bib5], [@bib6].Fig. 1An overview of the subsystem categories assigned to the genome of *Enterobacter cloacae* TREC1. The whole genome sequence of the strain TREC1 was annotated using the Rapid Annotation System Technology (RAST) server. The pie chart demonstrates the count of each subsystem feature and the subsystem coverage.Fig. 1
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